Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229–54.
2. Pfizer. Pfizer, CAMPTOSAR® (irinotecan HCl) prescribing information. 2021. https://www.pfizermedicalinformation.com/en-us/camptosar. Accessed 24 Mar 2021.
3. Ipsen. Ipsen, ONIVYDE® (irinotecan liposome) prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf. Accessed 4 Mar 2021.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14.
5. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for “Can’t Predict Toxicity”? J Clin Oncol. 2002;20:7–8.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献